Over 70% of patients achieved PASI 90 and more than 80% reached PGA 0/1 at Week 16, demonstrating significant efficacy over placebo with no new safety signals.
In October 2026, Nuance Pharma announces the first patient dosed in the REACH Phase III trial, a randomized, double-blind, ...
Shanghai Zhimeng Biopharma, Inc. ( "Zhimeng Biopharma") announced that its independently developed next-generation potassium channel opener, CB03-154, intended for the treatment of amyotrophic lateral ...
Backed by GSK, Pfizer and Sanofi, the Cascade initiative will integrate single-cell sequencing and protein data to strengthen predictive models of human immune responses.
Alkermes plc announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results